WuXi AppTec (HKG:2359) has completed the sale of its WuXi Clinical Development Services (Shanghai) and WuXi MedKey Med-Tech Development (Shanghai) units to asset manager Hillhouse Investment Management, according to a Hong Kong bourse filing Monday.
Shares of the drug research company fell over 1% in midday trade Tuesday.
The firm said it received the first installment payment of the consideration in the amount of 1.54 billion yuan.